Drug Trial Radar · NCT02650804
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jul 6, 2016
Primary completion
Jun 11, 2019
Study completion Jun 11, 2019
Sponsor
- Lead sponsor
- BPGbioIndustry
- Sponsor type
- Industry
- First posted
- Jan 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and Europe.
Conditions
- Pancreatic Cancer
Interventions
BPM31510 Nanosuspension InjectionDrug
GemcitabineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment ResponseTime frame: 10 weeks (End of Cycle 2)
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Banner Health
Gilbert, Arizona
Mayo Clinic
Phoenix, Arizona
Global Cancer Research Institute, Inc.
Gilroy, California
Sarcoma Oncology Research Center
Santa Monica, California
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Atlantic Health System Morristown Medical Center
Morristown, New Jersey
Vita Medical Associates, P.C.
Bethlehem, Pennsylvania
Mary Crowley Cancer Research Center
Dallas, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
St Bartholomew's Hospital
London, United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom
The Beatson West of Scotland Cancer Centre
Glasgow, Strathclyde, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.